NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Graft-Versus-Host Disease

Countries: Japan

This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.

Eligibility overview

Sex: ALL

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with acute and chronic GVHD
* Patients treated with ruxolitinib

Exclusion Criteria:

None

Other protocol-defined inclusion/exclusion criteria may apply.

Locations (1)

Tokyo, Japan